Search by Drug Name, NDC or Jcode

    Internal Navigation

    HCPCS Details

    HCPC J9061
    Short Description Inj, amivantamab-vmjw
    Long Description Injection, amivantamab-vmjw, 2 mg
    Pricing indicator 51
    Coverage code C
    ASC payment group code YY
    BETOS2 code O1D
    Action code N
    Type of service 1
    Effective date 2022-01-01
    Date Added 2022-01-01

    HCPCS/NDC Cross-Walk

    NDC HCPC Description Drug Name Labeler Name HCPCS Dosage PKG Size PKG QTY Bill Units Bill Units PKG
    57894050101 J9061 Inj, amivantamab-vmjw Rybrevant JANSSEN BIOTECH, INC. 2 mg 7 1 175 175
    The ASP crosswalks are maintained by the Division of Data Analysis and Market Based Pricing to support ASP-based Medicare Part B payments only. The crosswalks are intended to help the public (including entities that submit manufacturer ASP data and providers who bill for drugs) understand which drug products (identified by NDCs) are assigned to which HCPCS billing codes. The crosswalks are not intended to be a comprehensive list of all drugs/NDCs available in the United States. The NDC to HCPCS Crosswalk also includes information on the NDC package size and the number of billable units (as defined by the HCPCS code descriptor). Comments on the file may be sent to [email protected].

    HCPCS Billing Calculator

    Dosage given to patient (per dose)
    HCPCS Dosage 2 mg
    HCPCS/CPT Billing Units 0.5
    Total doses ordered
    Billing Units 0.5

    Drug Details

    • Amivantamab-vmjw injection is used to treat a certain type of non-small cell lung cancer (NSCLC) that spread to other parts of the body or cannot be removed by surgery, and has worsened either during or after treatment with platinum chemotherapy medications. Amivantamab-vmjw injection is in a class of medications called bispecific antibodies. It works by helping your immune system to slow or stop the growth of cancer cells.